The application of engineered EVs in the treatment of several pathological conditions, including cardiovascular, neurological, autoimmune, and cancer diseases, are summarized, and the major challenges in clinical translation and future perspectives for EV-based targeted therapies are discussed.
Abstract
Achieving precise and efficient targeting represents a major challenge in drug delivery to overcome the limitations of conventional therapies. Surface functionalization of extracellular vesicles (EVs)-nanosized membranous particles released by all cell types- has emerged as a promising strategy to enhance targeted drug delivery. EVs are naturally involved in intercellular communication by transferring bioactive molecules from donor to recipient cells, and their biologically active interface confers inherent targeting properties and a favorable safety profile, making them attractive vehicles compared to synthetic nanoparticles. However, the naїve use of EVs is often limited by nonspecific biodistribution and off-target accumulation, reducing their therapeutic efficacy. To overcome these limitations, increasing efforts have focused on engineering EVs through cargo loading and surface functionalization strategies, enabling enhanced targeting and improved delivery of therapeutic molecules. In this review, we first describe the biological features of EVs, including their biogenesis, heterogeneity, and molecular composition, which underlie their potential as drug delivery systems. We then discuss the main determinants of EV-mediated drug delivery and present current engineering strategies, including cargo loading and surface functionalization approaches, highlighting their advantages and limitations. Finally, we summarize the application of engineered EVs in the treatment of several pathological conditions, including cardiovascular, neurological, autoimmune, and cancer diseases, and discuss the major challenges in clinical translation and future perspectives for EV-based targeted therapies.
Nanomedicine harnesses the unique benefits of nanocarriers to markedly enhance drugs targeting tumors, which is becoming a promising approach to achieve precise and effective antitumor therapy. Extracellular vesicles (EVs), natural nanoscale entities, have garnered extensive attention due to their high biocompatibility...
Xuan-Han Zhang, Xiao-Wei Zhou, S. Fu et al.· Pharmaceutics· 0 citations
Small interfering RNA (siRNA) therapeutics have emerged as a transformative approach for sequence-specific gene silencing, offering the potential to treat a broad spectrum of diseases by selectively suppressing disease-associated genes. However, the clinical translation of siRNA remains limited by rapid enzymatic degra...
G. S. Amrish Varshan, S. Namasivayam· Nanomedicine: Nanotechnology...· 0 citations
Extracellular vesicles (EVs), particularly stem cell-derived exosomes, serve as vital natural nanocarriers in regenerative medicine, immune modulation, and targeted drug delivery due to their innate ability to transport bioactive cargo across complex biological barriers. Despite this potential, the therapeutic efficacy...
Extracellular vesicles (EVs) are membrane-bound, nano-sized particles released by diverse cell types. They serve as key mediators of intercellular communication by transporting a broad repertoire of proteins, lipids, nucleic acids, and metabolites to recipient cells within a protective lipid bilayer. Owing to their nat...
Nawaz Khan, Zeynab Ahmadova, Yu-Jie Shi et al.· Molecular Biomedicine· 0 citations
This review provides a comprehensive and critical overview of recent advances in the engineering strategies, biological membrane sources, and biomedical applications of BCNCs and critically evaluates the biological advantages, therapeutic potential, and translational limitations associated with different membrane sourc...
Fatemeh Mahmoudian, A. Ahmari, Somayeh Shamlou et al.· BioNanoScience· 0 citations
This review provides a biologically informed roadmap for designing efficient gene delivery vectors, proposing membrane-integrated nanovesicles (NVs) as "living interfaces" for non-viral gene therapy.
Clara Baldari, Claudia Leone, G. Leccese et al.· Advanced Healthcare Material...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.